The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice

• मुख्य लेखकों: Vincenzo Micale (लेखक), Filippo Drago (लेखक), Pia K. Noerregaard (लेखक), Christian E. Elling (लेखक), Carsten T. Wotjak (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Rimonabant was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was withdrawn from market due to the notably increased rates of psychiatric side effects. We have evaluated TM38837, a novel, largely peripherally...